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VIEWPOINT 
 
There is no shortage of US healthcare research centers advocating the adoption of 
innovations from other countries. The Institute for Healthcare Improvement 
(Boston, MA), The Commonwealth Fund (New York, NY), Innovations in Health at 
Duke University (Durham, NC), and the Network for Excellence in Healthcare 
Innovation (Cambridge, MA) are all promoting innovations from low-, middle- and 
high-income countries for potential adoption into the US.  However does it matter to 
their audience if a proposed innovation is from India, rather than from, say, Sweden; 
or from Rwanda, rather than from say, the United Kingdom? Very little is known 
about whether, and how, the country of origin of a proposed innovation matters in 
its diffusion.  
 
The question of country of origin matters considerably to those in the marketing 
industry. Research spanning several decades has shown that up to 30% of a 
consumer’s attitude to a product can be influenced by the country of origin of that 
product [1].  There is a complex interaction between the product type, where it is 
from, where the consumer is from, the demographic characteristics of the consumer 
and the geo-political characteristics of the two countries.  For example, products 
from England tend to be rated higher by Indian students than by Taiwanese 
students, because of the colonial ties between India and England. Caucasian 
consumers tend to rate products from North America more highly than non-
Caucasian consumers, who instead rated products from Nigeria, Latin America and 
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India more highly. Complex as this interaction is, it is also likely to change over time 
as preferences, political ties, and cultures constantly shift and change as well.  
 
The diffusion of innovation literature in healthcare is silent on the issue.  Rogers 
limits his diffusion of innovation theory only to the characteristics of the adopter 
[2]. Greenhalgh et al [3] incorporate characteristics of the adopting organization, of 
the innovation and of the change process but not of the source. Damschroder et al 
adds to Greenhalgh’s model and refers to the source of the innovation needing to be 
‘legitimate’ but sheds little light on what constitutes legitimate, for whom and under 
what circumstances [4].  In their international study of the cultural dynamics to 
support innovation diffusion, Keown et al (2014) note the importance of 
empowering patients, engaging health professionals, promoting learning, refining 
the innovation and eliminating legacy practices, but again little on the effect of the 
source of an innovation [5].  
 
None of these models or theories refers to the role of the adopters’-perception-of-
the-innovator-source as a mediating factor in the spread of an innovation. This is 
perhaps because it does not fit neatly into current conceptualizations of mediating 
factors in innovation diffusion i.e. is it a feature of the innovation, or of the adopter, 
or of both? 
 
The paucity of research in this area could lead  to the assumption that even though 
country of origin matters when choosing to purchase products such as a car or some 
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foods, it does not apparently matter when choosing whether to pilot a healthcare 
innovation so long as the innovation has been approved by the adopting country’s 
regulatory body. The reality is that the effect that source may have on our 
perception of an innovation is simply a neglected and yet potentially considerably 
significant issue for both providers and recipients of healthcare.  Some evidence  
suggests that the country of origin matters in research evaluation and publication. A 
recent randomized, controlled trial showed that a source from a low-income 
country negatively influenced US public health professors’ opinion of research 
abstracts in some instances [6].  Participants were more likely to refer one abstract, 
of the four abstracts that were included in the trial, to a peer if the source was from 
a high-income country compared to a low-income country (OR 1.28; 95%CI 1.02-
1.62).  Although the effect of size was small under experimental conditions, it may 
be  ‘clinically’ significant considering how much research is published and 
consumed on a daily basis.  This study established a benchmark with respect to the 
measurable effect of source on research interpretation and evaluation but needs to 
be repeated using different types of healthcare professionals and different types of 
research abstracts as well as the relationship between perception of research and of 
innovation.  
 
The so-called Reverse Innovation process – the adoption of low-income country 
innovations into high-income country contexts – is thwarted in part by  perceptions 
that low-income countries are unlikely to offer innovations of value and that these 
contexts are ‘too different’ from their own for the innovation to ‘fit’ [7]. This will 
 5 
lead to missed opportunities to learn from many exciting innovations arising from 
these contexts, in areas as diverse as cardiac surgery, ophthalmic surgery, 
community health workers, mobile phone screening apps, diagnostic support tools, 
and ambulatory services. For example, Narayana and Aravind are widely acclaimed 
Indian healthcare models in cardiac and ophthalmic surgery, respectively, yet they 
have not successfully diffused into more developed markets. The Brazilian Family 
Health Strategy systematically deploys over 250,000 Community Health Workers to 
provide cradle-to-grave health advice, universally, through home visits.  Peek Vision 
is a mobile phone based tool for retinography imaging used in Kenya.  Ziqitza uses 
novel cost-sharing finance model to provide ambulance services to poor 
communities in India.   
 
Understandably most innovations must be incorporated into delivery systems, and 
how healthcare is financed, organized, and delivered varies from country to country.  
Adoption processes are likely to be different for services and products.  However, 
given that no two, even neighboring, contexts are the same, differential preference 
for innovations from one country as opposed to another speaks to biases rather 
than objective assessments of the reality. To this extent, methodologies from the 
cognitive psychology literature can be used to examine further assumptions, biases 
and prejudices [8] concerning how we determine what is and what is not 
generalizable from one context to another. 
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More research is needed to better understand the effect of source in interpretation 
of healthcare research and in the  appetite to learn from other countries. It is time to 
establish a comprehensive research agenda that applies the knowledge and 
methods from the marketing and consumer affairs literatures to the assessment of 
healthcare research and innovation.  Just as the marketing literature examines the 
effect of the phrase ‘Made in [country]’, research into the effect of the phrase 
‘Authors’ affiliation’ in biomedical research is needed.  It is important to know, using 
adequately powered, controlled studies, whether research from certain institutions 
has been given less attention and credibility than from others, all other things being 
equal.   It must be clear if the powerful brand associated with high-impact journals 
influences readers’ perceptions of the research, all things being equal.  The relative 
importance of where the research was conducted compared to who conducted it 
and where it was published needs to be clarified.  For example, what is the relative 
importance of bibliometric or scientometric markers of legitimacy, such as citation 
indices, to organizational markers of legitimacy such as university rankings, to 
socio-economic measures of legitimacy, such as GDP/capita, Human Development 
Index, infant mortality rates, and Gini Index. 
 
In addition, the interactions between these characteristics and those of the 
‘Consumer’ (the Healthcare professional or equivalent) and the ‘Product’ (the 
research article or the innovation) need to be assessed.  Using adequately powered, 
controlled studies, how is the source of a research article or innovation affected by 
the age, sex, race, academic, clinical or managerial experience of the person 
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reviewing it, and how this changes by the type of innovation - technological 
innovations, service delivery innovations or pharmaceutical intervention.  For 
example, are US healthcare managers more amenable to adopting technological 
innovations from the United Kingdom than US clinicians?  Is this the case if the 
innovation is from Sweden, or Rwanda?  Or if it is a service delivery innovation? 
Does it matter if it is published in a high impact, widely disseminated, general 
medical journal (such as JAMA or the New England Journal of Medicine) or a more 
focused journal (such as the Scandinavian Journal of Public Health)? 
 
Significant resources are allocated to better understand the influence of country of 
origin for consumers.  Advertising agencies go to great lengths to develop counter-
stereotyping and stereotyping campaigns and to create effective brands that build 
on (or indeed minimize) the image of the source country.  It is why it is acceptable to 
perceive that cars from Japan are efficient, chocolate from Switzerland is delicious 
and that perfume from France is of high quality.  To dissipate any risk to its brand, 
perhaps this is why Apple writes on all phones “Designed in California, 
Manufactured in China”. A consumer might have considerably different perceptions 
of cars, chocolate and perfume if those products were from Ethiopia, Botswana and 
India respectively.  These stereotypes are enduring and well managed through the 
long-standing efforts of manufacturers and advertisers.    
 
It is time to examine much more closely how these preferences affect the evaluation 
of research, and influence the diffusion of healthcare innovations.  
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